Clinical Trial

Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

Study acronym: ELEVATE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety and the effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery system, named MiniMed NMX8 system (referred also to as NMX8 system), in comparison with other commercially available AID systems (Automated insulin delivery) in adult patients with Type 1 diabetes not achieving target clinical outcomes.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2027-11-04 -> 2027-12-04 2026-04-29
minor Completion pushed: 2028-02-28 -> 2028-03-29 2026-04-29
notable Sponsor changed: Medtronic Diabetes -> Medtronic MiniMed, Inc. 2026-04-19
Trial Details
NCT Number NCT07401901
Lead Sponsor Medtronic MiniMed, Inc.
Conditions Type 1 Diabetes (T1D)
Enrollment 230 participants
Start Date 2026-10-15
Primary Completion 2027-12-04 (estimated)
Study Completion 2028-03-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-28